NCT07352514 Use of PEA and Scutellaria in Synergy With Therapeutic Exercise in Chemotherapy-induced Peripheral Neuropathy (CIPN): a Clinical Trial
| NCT ID | NCT07352514 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Palermo |
| Condition | Chemotherapy-induced Peripheral Neuropathy (CIPN) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-15 |
| Primary Completion | 2026-02-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-03-15 with a primary completion date of 2026-02-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to find out if taking specific dietary supplements (PEA and Scutellaria) along with therapeutic exercise can help reduce nerve pain and damage caused by chemotherapy. Many cancer patients experience nerve-related side effects from chemotherapy, which can significantly impact their quality of life. The study will observe patients who use these supplements and exercises to see if they can effectively manage and improve their nerve health and reduce pain.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and older. * Patients who have undergone chemotherapy treatment within the previous 6 months. * Patients treated with PEA, Scutellaria, and standardized therapeutic exercise according to the EXCAP protocol from April 2025 to September 2025. * Patients with a washout period from opioid-based analgesic therapy of at least 10 days or who are not receiving opioid-based analgesic therapy. * Patients presenting with neuropathic pain (NRS ≥ 5). * Patients able to provide written informed consent. Exclusion Criteria: * Patients younger than 18 years. * Patients with hypersensitivity to PEA or any of the excipients listed in the Summary of Product Characteristics (SPC). * Patients with diabetic pathology. * Patients with severe hepatic impairment. * Patients with severe disabilities that compromise the execution of therapeutic exercise.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07352514 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy-induced Peripheral Neuropathy (CIPN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07352514 currently recruiting?
Yes, NCT07352514 is actively recruiting participants. Contact the research team at giulia.letiziamauro@unipa.it for enrollment information.
Where is the NCT07352514 trial being conducted?
This trial is being conducted at Palermo, Italy.
Who is sponsoring the NCT07352514 clinical trial?
NCT07352514 is sponsored by University of Palermo. The trial plans to enroll 40 participants.